Figure 4: Human ApoE3 levels in Apoe−/− mice after treatment with HDAd. A. PEPCK expression cassette. *p<0.05 vs. HDAd-P-E3 (n=5/group). B. APOAI cassette. *p<0.05 vs. HDAd-AIW-E3 at 2 weeks, **p<0.01 vs. HDAd-AIW-E3 and HDAd-AIWL at 1 week. C. APOE expression cassette. *p<0.05 vs. HDAd-EW-E3 and HDAdgE3, **p<0.01 vs. HDAd-EW-E3 and HDAd-gE3, and †p<0.05 vs. HDAd-EW-E3. D. Plasma apoE3 levels in mice treated with HDAd-gE3-D21. *p<0.05 vs. HDAd-gE3, **p<0.01 vs. HDAd-gE3.